RNA editing startup launches with $30M based on Stanford and University of Tübingen research

Ryan Cross

Senior Science Correspondent

The race to develop new therapies that precisely edit short-lived RNA molecules instead of making irreversible changes to DNA is heating up. A new entrant …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

RNA editing startup launches with $30M based on Stanford and University of Tübingen research

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

RNA edit­ing start­up launch­es with $30M based on Stan­ford and Uni­ver­si­ty of Tübin­gen re­search

Senior Science Correspondent

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

RNA editing startup launches with $30M based on Stanford and University of Tübingen research